BeyondSpring presents interim phase 2 data on 303 study

BeyondSpring (BYSI) announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer, NSCLC, after disease progression on 1L PD-1/L1 inhibitors with and without chemotherapy, with financial support from Merck’s Investigator Studies Program and provision of study drug, at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting, on May 31st, 2025 in Chicago, IL. The single study finished enrollment of 47 patients with patients treated with Plinabulin, pembrolizumab and docetaxel on day 1 of each cycle until disease progression or intolerable severe adverse events. As of the data cut-off date of May 16, 2025, there are patients still responding to the therapy; therefore, the final data will be updated. Median Progression-Free Survival: 6.8 months – nearly double the 3.7 months seen with current standard of care docetaxel. Confirmed Objective Response Rate: 18.2% – higher than the 12.8% seen with SOC docetaxel. Disease Control Rate: 77.3% – indicating clinical benefit majority of patients who progressed on prior PD-1/L1 inhibitors. Median Duration of Response: 7.2 months. 6-Month PFS Rate: 56%. 15-Month Overall Survival Rate: 78% – longer than median OS of 11.8 months for SOC docetaxel. The combination was well tolerated. 51.1% of patients experienced grade 3 or higher treatment-related adverse effects, including GI side effects of 14.9% and transient hypertension of 14.9%. There were no treatment-related deaths.